Biovail Names Dr. Michael Yeomans Senior Vice-President, Global Business Development.TORONTO, Ontario -- Biovail Corporation (NYSE NYSE See: New York Stock Exchange :BVF BVF Biovail Corporation (stock symbol) BVF Berufsverband der Frauenärzte eV (Muenchen, Germany) BVF Bearing Versus Frequency )(TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension :BVF) today announced that it has appointed veteran pharmaceutical industry executive Dr. Michael Yeomans Senior Vice-President, Global Business Development. Dr. Yeomans, who joins Biovail today, will be based at the company's offices in Bridgewater, N.J., and will be responsible for identifying and initiating new business-development activities -- including product licensing deals, patent licenses, strategic alliances, joint-ventures, and the acquisition of drug-delivery technologies. His mandate will also include aligning the activities of Biovail's global business-development group with the company's current and emerging strategic direction. "Biovail is actively exploring many new product-development and business opportunities," said Doug Squires, Chief Executive Officer of Biovail Corporation. "Dr. Yeomans brings more than 30 years of industry knowledge to Biovail. His expertise and experience with the business-development and licensing operation of a global pharmaceutical company, combined with his research and clinical development experience, fits well with Biovail's current and emerging requirements as we continue to identify opportunities to enhance shareholder value." Most recently, Dr. Yeomans was Senior Vice-President, Head of Global Business Development for Aventis Pharma. During his tenure, he was responsible for all business-development and licensing activities for Aventis -- from early-stage compounds to marketed products. More specifically, the scope of his mandate included product in-licensing and out-licensing; joint ventures; strategic alliances; technology acquisitions; and evaluation of new business opportunities. Before joining Aventis in 2000, Dr. Yeomans spent more than 27 years with the Hoechst Group, where he held a series of progressively responsible senior positions in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. and Germany, including Vice-President, Licensing and Alliances; Executive Director, Head, Pharma Business Development Group; Director, Licensing, Strategic Planning Strategic planning is an organization's process of defining its strategy, or direction, and making decisions on allocating its resources to pursue this strategy, including its capital and people. and Business Development; and Corporate Directorate Manager, Pharmaceutical Affairs. Dr. Yeomans spent the earlier part of his career in clinical research and drug development. From 1981-1986, he was a Project Manager and Registration Co-Ordinator in Hoechst's clinical research department based in Frankfurt, where he planned and implemented worldwide clinical-trial and registration programs. Previously, he spent four years working as a project team leader in the company's drug-discovery department in the United Kingdom. He spent his first four years at Hoechst as a member of the company's preclinical drug-development group in the U.K. Dr. Yeomans earned his Ph.D. in Organic Chemistry and a B.Sc. Honors degree in Chemistry from the University of London For most practical purposes, ranging from admission of students to negotiating funding from the government, the 19 constituent colleges are treated as individual universities. Within the university federation they are known as Recognised Bodies . About Biovail Corporation Biovail Corporation is an international full-service pharmaceutical company, engaged in the formulation, clinical testing, registration, manufacture, sale and promotion of pharmaceutical products utilizing advanced drug-delivery technologies. For more information about Biovail, visit the company's Web site at www.biovail.com. For further information, please contact Ken Howling at 905-286-3000 or send inquiries to ir@biovail.com. "Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " Statement Under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 To the extent any statements made in this release contain information that is not historical, these statements are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements on our current expectations and projections about future events. Our actual results could differ materially from those discussed in, or implied by, these forward-looking statements. Forward-looking statements are identified by words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Forward-looking statements include, but are not necessarily limited to, risks and uncertainties, including the difficulty of predicting U.S. Food and Drug Administration ("FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ") and Canadian Therapeutic Products Directorate Therapeutic Products Directorate (TPD) is a Canadian federal authority that regulates pharmaceutical drugs and medical devices for human use, a role performed by the Food and Drug Administration in the United States. ("TPD TPD Tons Per Day TPD Therapeutic Products Directorate TPD Total and Permanent Disablement (insurance) TPD Temperature Programmed Desorption TPD Temporary Partial Disability (insurance) ") approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials and finished products, third parties, the regulatory environment, fluctuations in operating results and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission ("SEC") and the Ontario Securities Commission The Ontario Securities Commission (OSC) is a regulatory agency which administers and enforces securities legislation in the Canadian province of Ontario. The OSC is an Ontario Crown corporation which reports to the Ontario legislature through the Minister of Finance. ("OSC O.S.C. n. short for Order to Show Cause. (See: Order to Show Cause) "). Biovail Corporation undertakes no obligation to update or revise any forward-looking statement. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion